Pendulum Therapeutics

Pendulum isn't another Lactobacillus-and-Bifidobacterium blend — it's built around next-generation anaerobic strains that are genuinely hard to find in any other US product, aimed at metabolic and gut health rather than generic "digestive support."

The lineup includes Akkermansia muciniphila WB-STR-0001, Clostridium beijerinckii WB-STR-0005, C. butyricum WB-STR-0006, Eubacterium hallii WB-STR-0008, and Bifidobacterium infantis 100, grown in an oxygen-free US facility and delivered in delayed-release capsules (Nutraceutical Business Review, practitioner writeup). Dosing is only partially disclosed — Pendulum publishes gross totals (e.g., Akkermansia at 100 million AFU) but not the split across individual strains in combo products (Innerbody).

The brand states third-party testing at an ISO 17025-certified lab, cGMP manufacturing, and GRAS designation for each microbe in Glucose Control (Amazon listing, Nutraceutical Business Review), though an independent audit found GMP certification but no NSF/USP/Informed Sport mark (SupplementChecker).

No recalls or warning letters on record, but several on-site benefit claims lean on consumer surveys of 80-172 people rather than RCTs, and pricing is high — Akkermansia runs $54-84/month (Pendulum, Innerbody). A peer-reviewed RCT of Glucose Control did publish in BMJ Open Diabetes Research & Care, which is more clinical backing than most probiotics can claim (BMJ Open DRC). Compared to BioGaia's single well-studied strain, Pendulum trades dosing transparency for strain novelty.